Merger

Five things for pharma marketers to know: Monday, November 17

Five things for pharma marketers to know: Monday, November 17

By

Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.

Five things for pharma marketers to know: Friday, November 14

Five things for pharma marketers to know: Friday, November 14

By By

Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.

Valeant wins over docs with trips, fees

Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.

Becton Dickinson buys CareFusion

An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

By

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

By

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

By

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

By

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, August 27

By

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

By

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Shire asks AbbVie for more money

Shire asks AbbVie for more money

By

Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.

NuPathe dumps Endo

NuPathe decided Teva's $144-million offer was a better fit, ending its possible Endo merger.

Business briefs: Novartis, Regeneron and Pfizer

Novartis prepares for a strategic review that hints at scuttling lesser-performing businesses; Regeneron's Eylea sales prompt expansion; Pfizer targets diabetes and obesity; and the FDA approves an MS stem cell trial

Business briefs: Elan and Valeant

Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.

Publicis Omnicom merger puts healthcare clients under one roof

Publicis Omnicom merger puts healthcare clients under one roof

By

Over the weekend, Publicis Omnicom vaulted past WPP to become the world's biggest ad holding company. The task now falls on its co-CEOs to sort out any conflicts and prevent defections.

Culture of innovation has a sales value, study says

Culture of innovation has a sales value, study says

By

Why executives evaluating biotech acquisitions shouldn't overlook the cultural dimension: A new paper finds a link to revenue performance.

J&J consolidates, rebrands Ethicon units

J&J consolidates, rebrands Ethicon units

By

Driven by consolidation in the healthcare industry, J&J is reuniting Ethicon, Inc. and Ethicon Endo-Surgery to present surgeons and health systems with a single face.

Pharmas to biotechs: let's make a deal

Pharmas to biotechs: let's make a deal

By

Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.

After rough '12, PHCG looks to inject more life into business

By

An agency bellwether, PHCG is hoping to return to growth after a tame 2012, its CEO said this week.

Between the lines, Read offers investors a split preview

Between the lines, Read offers investors a split preview

By

The Pfizer chief told investors that the company will provide "transparency" on its new and established products businesses, with a view toward a possible Abbott-esque spinoff down the road

Business briefs: LifeScan, Havas Health

LifeScan's new glucose monitor gets an FDA green light; Havas Health merges two London shops and refreshes H4B branding

Ex-Pfizer chief takes over at troubled Optimer

Ex-Pfizer chief takes over at troubled Optimer

By

Former Pfizer chieftain Hank McKinnell is taking the reins at stock scandal-plagued Optimer—perchance to sell it to Pfizer?

With digital no longer special, InVentiv merges four agencies into two

By

InVentiv is merging two of its digital agencies into two full-service shops: GSW, Fueled by Blue Diesel and Ignite + Palio.

Company news: Edelman, Pfizer, Publicis, Lippincott

Healthcare PR giant Dan Edelman dies; Pfizer says 'no comment' on breakup speculation; Publicis Healthcare snags a new SVP; Lippincott gives nurses a new drug diagnosis tool.

Company news: Pfizer, Vertex and Poz

Pfizer and at least two other pharmas are spreading pink slips instead of cheer

Havas merges transatlantic duo of digital shops

By

Havas is merging two digital shops, Euro RSCG Life 4D and Creative Lynx, to form Havas Lynx, a transatlantic full service group that will serve as a mini-network alongside Havas Life and Health4Brands.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters